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A BS TR AC T
Background
The molecular causes of many hematologic cancers remain unclear. Among these 
cancers are chronic neutrophilic leukemia (CNL) and atypical (BCR-ABL1–negative) 
chronic myeloid leukemia (CML), both of which are diagnosed on the basis of neo-
plastic expansion of granulocytic cells and exclusion of genetic drivers that are 
known to occur in other myeloproliferative neoplasms and myeloproliferative– 
myelodysplastic overlap neoplasms.
Methods
To identify potential genetic drivers in these disorders, we used an integrated ap-
proach of deep sequencing coupled with the screening of primary leukemia cells ob-
tained from patients with CNL or atypical CML against panels of tyrosine kinase–
specific small interfering RNAs or small-molecule kinase inhibitors. We validated 
candidate oncogenes using in vitro transformation assays, and drug sensitivities 
were validated with the use of assays of primary-cell colonies.
Results
We identified activating mutations in the gene encoding the receptor for colony-
stimulating factor 3 (CSF3R) in 16 of 27 patients (59%) with CNL or atypical CML. 
These mutations segregate within two distinct regions of CSF3R and lead to pre-
ferential downstream kinase signaling through SRC family–TNK2 or JAK kinases 
and differential sensitivity to kinase inhibitors. A patient with CNL carrying a JAK-
activating CSF3R mutation had marked clinical improvement after the administra-
tion of the JAK1/2 inhibitor ruxolitinib.
Conclusions
Mutations in CSF3R are common in patients with CNL or atypical CML and repre-
sent a potentially useful criterion for diagnosing these neoplasms. (Funded by the 
Leukemia and Lymphoma Society and others.)
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T herapy with small-molecule kinase inhibitors has improved the outcomes in patients who have certain types of cancer 
with kinase-pathway dependence caused by de-
fined genetic abnormalities.1,2 Extrapolation of 
this model to other cancers requires knowledge 
of operationally important genetic mutations 
that result in corresponding activation of kinase 
pathways. Despite advances in our understanding 
of the molecular pathobiology of certain types of 
hematologic cancers, many of these disorders are 
still diagnosed on the basis of neoplastic cell 
type and additional exclusionary criteria.
Chronic neutrophilic leukemia (CNL) and 
atypical chronic myeloid leukemia (CML) are rare 
hematologic neoplasms that are characterized by 
leukocytosis and hypercellularity of bone marrow 
consisting predominantly of granulocytic cells, 
the absence of the Philadelphia chromosome with 
translocation t(9;22) (BCR-ABL1), and the absence 
of rearrangements in genes encoding platelet-
derived growth factor receptors alpha and beta 
(PDGFRA/B) and fibroblast growth factor receptor 1 
(FGFR1). CNL is diagnosed on the basis of the 
expansion of neutrophils in both bone marrow 
and blood (segmented neutrophils and band 
forms, >80% of white cells) and is classified as 
a myeloproliferative neoplasm, according to World 
Health Organization (WHO) diagnostic criteria. 
(A histopathological sample from a patient with 
CNL is provided in Fig. S1 in the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org.)
Atypical CML is characterized by granulocytic 
dysplasia and an increased number of neutrophil 
precursors in both the peripheral blood and the 
bone marrow (typically, ≥10% of white cells) and is 
therefore classified as one subtype of the WHO 
category of myelodysplastic–myeloproliferative 
neoplasms.3,4 Some patients with CNL5,6 and most 
patients with atypical CML have nonspecific cyto-
genetic abnormalities7 or (infrequently) the JAK2 
V617F mutation,8,9 findings that reveal the clon-
al nature of these diseases. The genetic basis for 
both CNL and atypical CML remains unknown, 
although certain subtypes of myeloproliferative 
neoplasms have been operationally defined accord-
ing to the molecular abnormalities (e.g., BCR-ABL1 
in CML) or are characterized by a high frequency 
of specific genetic abnormalities (e.g., JAK2 
V617F in polycythemia vera, essential thrombo-
cythemia, and primary myelofibrosis8,10-13 and 
KIT D816V in systemic mastocytosis14,15).
CSF3R is the receptor for colony-stimulating 
factor 3 and is thought to play a prominent role 
in the growth and differentiation of granulo-
cytes.16,17 CSF3R mutations have been described 
in patients with severe congenital neutropenia, 
which can evolve into acute myeloid leukemia 
(AML).18-20 It was recently reported that in a 
patient with congenital neutropenia, a secondary 
CSF3R mutation developed at the time of trans-
formation to AML.21 These nonsense or frame-
shift mutations, which have been described previ-
ously, truncate the cytoplasmic tail of CSF3R, 
impair its internalization, and alter its interac-
tions with proteins such as SHP-1/2 and SOCS 
family members.22-24 These structural and func-
tional alterations are thought to perturb the ca-
pacity of CSF3R to regulate granulocyte differen-
tiation and to increase granulocytic proliferative 
capacity.25-27 CSF3R signals through the JAK–
STAT pathway, the nonreceptor tyrosine kinase 
SYK,28,29 and the SRC family kinase LYN. CSF3R 
signaling through LYN was recently shown to be 
mediated by the phosphatase SHP-2 and the 
adapter protein GAB2.28-31 With the exception of 
isolated case reports,32 mutations in CSF3R have 




All clinical samples were obtained after written 
and oral informed consent was provided by the 
patients. The study was approved by the institu-
tional review boards at the University of Texas 
Southwestern Medical Center, University of Colo-
rado, Stanford University, Washington University 
in St. Louis, or Oregon Health and Science Univer-
sity (OHSU). All studies in mice were performed 
according to a protocol approved by an OHSU 
committee on institutional animal care and use. 
No commercial support was provided for this 
study. Ruxolitinib was obtained through health 
care insurance for treatment of the index patient. 
An expanded description of the methods is pro-
vided in the Supplementary Appendix.
Deep Sequencing and Screening  
of Primary Cells
We hypothesized that patients with CNL or atyp-
ical CML may harbor oncogenes that would lead 
to sensitivity to small-molecule kinase inhibitors. 
To test this hypothesis, we used a functional- 
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genomics approach in evaluating primary cells 
from 27 patients with CNL or atypical CML, as 
well as specimens from patients with a variety of 
other hematologic cancers. We performed deep 
sequencing with coverage of coding regions of 
1862 genes representing all kinases, phospha-
tases, non-kinase growth factor or cytokine re-
ceptors, and selected adapter genes (Tables S1 
and S2 in the Supplementary Appendix). Wher-
ever possible, we also screened these primary 
leukemia cells against panels of tyrosine kinase–
specific small interfering RNAs (siRNAs)33,34 or 
small-molecule kinase inhibitors.35 We previously 
validated this approach on specimens with proof-
of-principle molecular lesions (e.g., BCR-ABL1, 
FLT3-ITD, JAK2 V617F, and KRAS G13D), and we 
also used this strategy to identify previously un-
known molecular targets in leukemia specimens 
(e.g., two base-pair “GG” insertions at position 
1886 of the myeloproliferative leukemia virus on-
cogene [MPL1886InsGG] and ROR1).33-35
R esult s
Frequency of CSF3R Mutations
We found enrichment of mutations in CSF3R in 
16 of 27 patients (59%) with CNL or atypical CML 
(Table 1 and Fig. 1A, and Table S3 in the Supple-
mentary Appendix). Sequence variants that were 
identified included membrane proximal muta-
tions (T615A and T618I) and a number of differ-
ent frameshift or nonsense mutations that trun-
cate the cytoplasmic tail of CSF3R (D771fs, 
S783fs, Y752X, and W791X). Similar mutations 
that truncate the CSF3R cytoplasmic domain have 
been described in patients with congenital neu-
tropenia that progresses to AML after long-term 
treatment with granulocyte colony-stimulating fac-
tor (G-CSF).18-20 Representative deep-sequencing 
data and validation on Sanger sequencing for pa-
tients with mutant CSF3R are shown in Figures S2 
and S3 in the Supplementary Appendix. Five pa-
tients (Patients 3 through 7) had both membrane 
proximal and truncation mutations (Table S3 in 
the Supplementary Appendix), and we confirmed 
that these compound mutations can occur on the 
same CSF3R allele with no requisite order for se-
quential acquisition of mutations (Table S4 in the 
Supplementary Appendix).
We identified a CSF3R mutation in 1 of 92 pa-
tients with AML, and 2 of 200 patients with AML 
in the Cancer Genome Atlas AML data set had a 
CSF3R mutation,21 indicating that the incidence 
of such mutations in AML is low (1%) (Table 1). 
We identified a CSF3R membrane proximal muta-
tion (T618I) in 1 of 3 patients with early T-cell 
precursor T-cell acute lymphoblastic leukemia 
(ETP-T-ALL) (Table 1, and Fig. S4 in the Supple-
mentary Appendix). We found no additional CSF3R 
mutations in 8 patients with T-cell ALL or 41 pa-
tients with B-cell ALL (Table 1). Finally, we se-
quenced samples from 3 patients with reactive 
neutrophilia, and none had CSF3R mutations. 
Taken together, these data suggest that muta-
tions in CSF3R are a defining molecular abnor-
mality of CNL and atypical CML, and testing for 
CSF3R mutations could aid in the diagnosis of 
these diseases.
Dependence on SRC Family–TNK2 or JAK Kinases
We next sought to determine whether specimens 
harboring mutant CSF3R show in vitro sensitivity 
to small-molecule inhibitors of kinases or siRNA 
directed against kinases that become dysregulated 
downstream of mutant CSF3R. Analysis of cells 
from Patient 3, who had CNL with the CSF3R 
S783fs mutation (Table S3 and Fig. S2 in the Sup-
plementary Appendix), revealed dramatic sensitiv-
ity to the multikinase inhibitor dasatinib (Sprycel, 
Bristol-Myers Squibb) but no sensitivity to inhibi-
tors of JAK family kinases (Fig. 1B). Further in-
terrogation with our panel of tyrosine kinase–
specific siRNAs revealed sensitivity to silencing 
of tyrosine kinase nonreceptor 2 (TNK2) and an 
SRC family kinase, FGR, both of which are po-
tently inhibited by dasatinib36 (Fig. 1C). We also 
Table 1. Summary of CSF3R Mutational Status in the Study Samples, 





of Variant  
Frequency
no. of samples/ 
total no. %
Chronic neutrophilic leukemia or atypical 
chronic myeloid leukemia
16/27 59
Acute myeloid leukemia 3/292 1
T-cell acute lymphoblastic leukemia 0/8 0
Early T-cell precursor T-cell acute  
lymphoblastic leukemia
1/3 NA
B-cell acute lymphoblastic leukemia 0/41 0
* Data are based on deep sequencing and Sanger-sequencing validation of samples 
obtained from 27 patients with chronic neutrophilic leukemia or atypical chronic 
myeloid leukemia and from patients with the other listed hematologic cancers. 
NA denotes not available because of the small number of samples.
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performed drug-sensitivity profiling on samples 
from two patients with the CSF3R T618I mutation 
(one with CNL and one with ETP-T-ALL). In con-
trast to the drug-sensitivity pattern in the patients 
with truncation mutations, both samples showed 
sensitivity to inhibitors that target JAK family ki-
nases (including ruxolitinib [Jakafi, Incyte]) but 
resistance to dasatinib (Fig. 1D, and Fig. S3D and 
S3E in the Supplementary Appendix). Taken to-
gether, the functional genomic data on the sam-
ples from these three patients suggest that there 
are two different classes of CSF3R mutations: trun-
cation mutations, which result in dysregulation 
of SRC family–TNK2 kinases, and membrane 
proximal mutations, which result in dysregula-
tion of JAK family kinases. The data also suggest 
that truncation mutations confer sensitivity to 
dasatinib but not to JAK kinase inhibitors, where-
as the reverse is true for membrane proximal 
mutant cells.
Distinct Signaling-Pathway Dysregulation
To test the relative transforming capacity of trun-
cation mutations, as compared with membrane 
proximal mutations, in CSF3R, we performed an 
assay to measure cytokine-independent growth 
using the interleukin-3–dependent Ba/F3 cell line 
(Fig. 1E). Both classes of CSF3R mutations were 
capable of inducing transformation of Ba/F3 cells 
to interleukin-3–independent growth, and the 
membrane proximal mutations (T615A and T618I) 
transformed cells in this assay substantially fast-
er than did the truncation mutations (Q741X and 
S783fs).
Once we confirmed the transformation capac-
ity of the CSF3R mutations, we investigated the 
Figure 1 (facing page). Sensitivity to Kinase Inhibition in Leukemia Specimens with Transforming Mutations in CSF3R.
Panel A shows the location and recurrence of CSF3R mutations found in samples from 16 of 27 patients with chronic 
neutrophilic leukemia (CNL) or atypical chronic myeloid leukemia (CML), along with samples from patients with other 
types of leukemia. The mutation locations and number of observations are indicated by black circles. The Q741X 
mutation was found in a sample obtained from a patient with acute myeloid leukemia (AML), and one of the T618I 
mutations was found in a sample from a patient with early T-cell precursor T-cell acute lymphoblastic leukemia 
(ETP-T-ALL). Five patients with CNL or atypical CML had both membrane proximal and truncation mutations. (For 
details, see Table S3 in the Supplementary Appendix.) Two additional CSF3R mutations (Q739X and T618I, which are 
not shown) have been reported in AML specimens sequenced by the Cancer Genome Atlas.21 All CSF3R coordinates 
are numbered according to the conventions of the Ensembl genome browser, a numbering system that differs from 
historical CSF3R numbering owing to the inclusion of the 23-amino-acid signal peptide, despite the absence of this 
signal peptide from the mature protein. Panel B shows the sensitivity of white cells from Patient 3, who had CNL and 
a CSF3R S783fs mutation (Table S3 in the Supplementary Appendix), to a panel of 66 small-molecule kinase inhibitors. 
The 50% inhibitory concentration (IC50) of each drug is plotted as a percentage of the median IC50 for each drug 
from 150 samples obtained from patients with leukemia.35 A specimen was considered to be hypersensitive to an 
inhibitor if the IC50 was less than 10% of the median IC50 for that inhibitor for the entire cohort (as indicated by the 
dashed red line). This specimen was hypersensitive to dasatinib (green) and insensitive to JAK kinase inhibitors  
(orange). SFK denotes SRC-family kinase, and TNK2 tyrosine kinase nonreceptor 2. Panel C shows the sensitivity  
of white cells from Patient 3 to small interfering RNAs (siRNAs) directed against all known tyrosine kinases, as de-
scribed previously.33,34 Silencing of TNK2 and an SRC family kinase, FGR, resulted in a substantial decrease in cell 
viability. All cell-viability values after silencing with each individual siRNA have been normalized to the median value 
of the entire panel. The bars on the graph represent the mean normalized cell viability from triplicate data points for 
each individual siRNA. The T bars represent standard errors. The black horizontal line indicates the mean of all val-
ues across the entire siRNA panel, and the red dashed line indicates a threshold of significance, which is calculated 
as the mean minus 2 SD for all values. In addition to carrying the CSF3R S783fs mutation, Patient 3 had a minority 
of clones with a CSF3R S783fs–T615A compound mutation, but this small percentage of cells did not have an effect 
on sensitivity to inhibitors in short-term assays. Panel D shows the sensitivity of white cells from a patient with ETP-
T-ALL and a CSF3R T618I mutation to the same panel of 66 small-molecule kinase inhibitors that was used to test 
cells from Patient 3, as described in Panel B. These cells were insensitive to dasatinib (green) and sensitive to JAK  
kinase inhibitors (orange). Panel E shows interleukin-3–dependent Ba/F3 cells that were infected with murine retro-
virus expressing wild-type CSF3R, membrane proximal mutations, or truncation mutations. Uninfected parental Ba/
F3 cells and empty-vector infected Ba/F3 cells were used as controls. Over a 10-day period, both classes of CSF3R 
mutations were capable of transforming Ba/F3 cells to interleukin-3–independent growth, and the membrane proximal 
mutations (T615A and T618I) transformed cells in this assay substantially faster than the truncation mutants (Q741X 
and S783fs). Panel F shows Ba/F3 cells expressing CSF3R T618I or S783fs mutations before or after interleukin-3–
independent transformation (IL3− indicates transformed cells). Cell lysates were subjected to immunoblot analysis 
for CSF3R, TNK2, phospho-STAT3 (pSTAT3), total STAT3, phospho-JAK2 (pJAK2), total JAK2, phospho-SRC (pSRC), 
total SRC, and actin. Parental Ba/F3 cells or Ba/F3 cells expressing wild-type CSF3R were included as controls.
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differential signaling and drug sensitivity sug-
gested by our functional screening of samples of 
CSF3R mutant leukemia. Ba/F3 cells expressing 
the T618I or S783fs mutation before or after 
interleukin-3–independent transformation, along 
with cells expressing wild-type CSF3R or paren-
tal control cells, were starved of the interleukin-3 
growth factor, and cell lysates were analyzed by 
means of immunoblotting. The cells with the 
S783fs mutation showed higher expression of 
CSF3R than did the cells with the wild-type allele 
(Fig. 1F), and this difference was magnified after 
long-term culture in the absence of interleukin-3, 
a finding consistent with results of previous stud-
ies showing disruption of receptor internaliza-
tion in the context of truncation mutations.22-24,37 
After withdrawal of interleukin-3, Ba/F3 cells 
with CSF3R mutations expressed high levels of 
endogenous TNK2 and increased phosphoryla-
tion of SRC family kinases, providing validation 
of the initial TNK2 and FGR siRNA sensitivities 
observed in samples obtained from a patient with 
a CSF3R truncation mutation (Fig. 1C) and sug-
gesting that TNK2 is a previously unrecognized 
downstream mediator of CSF3R signaling.
To further investigate the potential signaling 
differences between the two classes of CSF3R mu-
tations, we performed immunoblot analysis for 
JAK–STAT phosphorylation. The T618I mutant 
induced high levels of STAT3 and JAK2 phos-
phorylation, in sharp contrast to the lower levels 
induced by the S783fs mutant (Fig. 1F). Taken 
together, these data indicate that the two classes 
of CSF3R mutations have different transforma-
tion potential and downstream signaling conse-
quences.
Use of Tyrosine Kinase Inhibitors
To further test the sensitivities of CSF3R trunca-
tion and membrane proximal mutations to in-
hibitors of SRC family–TNK2 or JAK kinases, we 
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CSF3R S783fs, CSF3R T618I, or an empty vector 
control and plated them in a colony-formation 
assay. The empty-vector control cells, which ex-
pressed endogenous levels of wild-type CSF3R, 
required 10 ng of exogenous G-CSF per milliliter 
to form colonies; in contrast, CSF3R S783fs mu-
tant cells required 0.4 ng of G-CSF per milliliter 
to elicit colony formation, and the T618I mutant 
grew in the absence of any added G-CSF.
Treatment with dasatinib had a dramatic ef-
fect on S783fs-driven colony formation, with a 
50% inhibitory concentration (IC50) of approxi-
mately 1 nM (Fig. 2A). The T618I mutant was 
relatively insensitive to dasatinib (IC50, approxi-
mately 100 nM), an observation that is consistent 
with the results for primary cells from patients, 
and the empty-vector control cells were com-
pletely insensitive to dasatinib. All cells showed 
similar sensitivity to the JAK kinase inhibitor 
ruxolitinib, with an IC50 of approximately 100 nM, 
which is equivalent to the sensitivity of cells with 
a defined JAK dependency38 (Fig. 2B).
The ruxolitinib sensitivity of the empty-vector 
and S783fs-mutant cells must be understood in the 
context of the requirement of exogenous G-CSF 
for the stimulation of colony growth, in which 
the exogenous G-CSF preferentially stimulates 
JAK–STAT signaling. Primary cells from patients 
with a CSF3R truncation mutation showed sensi-
tivity to dasatinib but not to JAK kinase inhibi-
tion when cultured in the absence of exogenous 
G-CSF (Fig. 1B and 1C). In contrast, colony for-
mation of the T618I cells showed sensitivity to 
ruxolitinib despite the fact that exogenous G-CSF 
was not required for colony outgrowth, a finding 
consistent with the sensitivity of primary cells 
from patients with CSF3R membrane proximal 
mutations to JAK kinase inhibition (Fig. 1D). 
Taken together, these data show that CSF3R trun-
cation mutants studied in vitro are sensitive to SRC 
family–TNK2 inhibitors, and membrane proximal 
mutants are sensitive to JAK kinase inhibitors.
Clinical Efficacy of Ruxolitinib in a Patient 
with CSF3R T618I
Primary cells from Patient 9, who had CNL with 
a CSF3R T618I mutation (Table S3 and Fig. S3C in 
the Supplementary Appendix), showed in vitro 
hypersensitivity to ruxolitinib (IC50, 127 nM) (Fig. 
S3E in the Supplementary Appendix). Treatment 
of this patient with oral ruxolitinib (at a dose of 
10 mg twice daily) resulted in a marked decrease 
in the total number of white cells and the abso-
lute neutrophil count (Fig. 2C). Increasing the 
dose of ruxolitinib to 15 mg twice daily led to a 
further decrease in both the white-cell count and 
the absolute neutrophil count. This treatment 
also resulted in normalization of the platelet 
count (Fig. 2D).
Discussion
Rapid improvements in sequencing technology 
have resulted in a wealth of cancer-genome data, 
but understanding which genomic aberrations 
can be targeted as sites for potential treatment 
remains challenging. By integrating functional 
and genomic analyses of primary leukemia spec-
imens, we identified CSF3R mutations as drivers 
of leukemia and also identified tyrosine kinase 
inhibitors that effectively target downstream 
CSF3R-signaling pathways. We found mutations 
in CSF3R in 59% of patients with CNL or atypical 
CML — myeloid neoplasms for which no disease-
specific genetic markers have been identified to 
date. The high frequency of activating mutations 
in CSF3R in these leukemias, which are character-
ized by high numbers of neutrophils, is consis-
tent with its function as the receptor for the 
growth factor that promotes neutrophil differen-
tiation and proliferation.16,17
The CSF3R mutations represent a biologically 
unifying feature of CNL and atypical CML and 
define a new molecular subset of hematologic 
cancers. The incorporation of CSF3R mutational 
status into current diagnostic criteria for CNL 
and atypical CML may help refine the molecular 
classification of myeloproliferative neoplasms 
and myeloproliferative–myelodysplastic overlap 
neoplasms. Although CNL and atypical CML are 
currently defined as separate neoplasms by the 
WHO, distinguishing between the two diagno-
ses can sometimes be challenging for clinicians 
and hematopathologists. The categorization re-
lies partly on arbitrary thresholds for the total 
white-cell count (e.g., ≥25,000 per cubic milli-
meter for CNL and ≥13,000 per cubic millimeter 
for atypical CML), the percentage of total white 
cells that are immature granulocytes (<10% for 
CNL and ≥10% for atypical CML), and the pres-
ence or absence of dysgranulopoiesis (absent in 
CNL and characteristic of atypical CML).
Similar to the identification of the JAK2 V617F 
mutation across a spectrum of related myelopro-
The New England Journal of Medicine 
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on March 25, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
CSF3R Mutations in Chronic Neutrophilic Leukemia
n engl j med 368;19 nejm.org may 9, 2013 1787
liferative neoplasms (e.g., polycythemia vera, es-
sential thrombocythemia, and primary myelofi-
brosis), the phenotype of CSF3R mutation–positive 
neoplasms may be modified by additional un-
known molecular abnormalities or host genetic 
factors, such as mutations in the gene encoding 
SET-binding protein 1 (SETBP1).39 In addition, as-
sessment of CSF3R mutational status may be use-
ful for the evaluation of diseases characterized 
by neutrophilia in which the clinical basis is not 
readily apparent.
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Figure 2. Use of Tyrosine Kinase Inhibitors to Treat Dysregulated Signaling Induced by CSF3R Mutations.
Panel A shows the effect of dasatinib on colony formation in bone marrow cells from mice that were infected with 
mutant CSF3R-containing retroviruses or an empty vector; the control cells expressed endogenous wild-type CSF3R. 
Cells were grown in methylcellulose containing the minimal amount of granulocyte colony-stimulating factor (G-CSF) 
necessary to form colonies (10 ng per milliliter for the empty vector, 0.4 ng per milliliter for the S783fs mutation, and 
no G-CSF for the T618I mutation). Cells were plated with increasing concentrations of dasatinib (0, 1, 10, 100, and 
1000 nM). The experiment was performed in triplicate with the number of colonies normalized to those in the un-
treated controls. Values represent the mean percent colonies; the T bars indicate standard errors. A single asterisk 
indicates P<0.07, and a double asterisk indicates P<0.005 for the comparison between the T618I mutation and the 
S783fs mutation at equivalent doses of dasatinib. Panel B shows the results of a similar colony-formation assay, in 
which the cells were plated with ruxolitinib (0, 10, 100, or 1000 nM). Panel C shows the results for Patient 9, who 
had CNL and a CSF3R T618I mutation and in whom earlier testing indicated sensitivity to ruxolitinib (Rux) in vitro 
(Fig. S3C and S3E in the Supplementary Appendix). This patient was treated with 500 mg of hydroxyurea (HU) daily 
starting on day 13. Hydroxyurea was stopped on day 21 and oral ruxolitinib (at a dose of 10 mg twice daily) was ad-
ministered. On day 70, the dose of ruxolitinib was increased to 15 mg twice daily. The numbers of white cells and 
neutrophils (absolute neutrophil count) are shown. Panel D shows normalized platelet counts while Patient 9 was 
undergoing the treatment regimen shown in Panel C.
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downstream SRC family and JAK-kinase path-
ways,28,29 and we have identified a novel CSF3R 
downstream substrate, TNK2. These downstream 
kinase pathways make CSF3R mutations an at-
tractive marker for tyrosine kinase inhibitors. 
The two types of CSF3R mutations may have dif-
ferential susceptibility to classes of tyrosine ki-
nase inhibitors, with CSF3R truncation mutations 
showing activation of SRC family–TNK2 kinase 
signaling and sensitivity to dasatinib, and CSF3R
membrane proximal mutations showing prefer-
ential activation of the JAK signaling pathway 
(Fig. 3). Our observation that a patient with a 
membrane proximal mutation had an excellent 
clinical response to the JAK inhibitor ruxolitinib, 
resulting in a marked decrease in the numbers 
of white cells and neutrophils and an increased 
platelet count (Fig. 2C and 2D), constitutes a 
proof of concept. Although anecdotal, this ob-
servation provides an impetus for further inves-
tigation of tyrosine kinase inhibitors for the 
treatment of patients with neutrophilic leukemia 
who have CSF3R mutations.
Although CSF3R truncation mutations have 
been shown to lead to constitutive overexpression 
of the receptor and ligand hypersensitivity,22-24,37
the mechanism of action of the membrane proxi-
mal mutation does not appear to involve similar 
receptor overexpression, since the membrane 
proximal mutants do not show analogous over-
expression in the Ba/F3 model (Fig. 1F). Our data 
show that T618I is capable of inducing colony 
formation in the absence of G-CSF ligand, which 
suggests constitutive activation of the receptor. 
Data from a recent study21 identified the same 
mutation in a patient with congenital neutrope-
nia and sequential acquisition of CSF3R mutations 

































Figure 3. Model for Activation and Signaling of CSF3R Mutations.
Truncation mutations in CSF3R (the receptor for G-CSF) result in increased expression levels. Downstream signaling mediators — SRC 
family kinases (SFKs) and TNK2 — are preferentially activated by these truncation mutations. Consequently, leukemic cells harboring 
the mutations are highly sensitive to dasatinib. Truncation mutations in CSF3R may also show sensitivity to JAK kinase inhibitors in the 
context of JAK kinase stimulation downstream of high ligand concentrations. In contrast, membrane proximal mutations in CSF3R show 
completely ligand-independent function. In this capacity, the dominant mode of signaling appears to operate through the JAK–STAT 
pathway. Thus, patients with membrane proximal mutations may be candidates for treatment with JAK kinase inhibitors, such as the 
JAK1/2 inhibitor ruxolitinib.
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several patients with CNL or atypical CML had 
both truncation and membrane proximal muta-
tions, and the signaling of these compound mu-
tations and their sensitivities to tyrosine kinase 
inhibition also warrant characterization in fu-
ture studies.
Complex genetic alterations are common in a 
multitude of tumor types. CSF3R truncation mu-
tations accelerate tumor formation in the pres-
ence of other genetic modifiers but alone are 
incapable of causing AML.40 Although CSF3R mu-
tations have been reported in patients with con-
genital neutropenia that progressed to AML, the 
prevalence of CSF3R mutations in de novo AML 
is low (approximately 1%).21 It is possible that 
this low frequency is due to the required contri-
bution from other genetic alterations for trans-
formation to AML.
In conclusion, the presence of CSF3R mutations 
identified a distinct diagnostic subgroup of more 
than 50% of patients with CNL or atypical CML 
in our study. The oncogenic CSF3R mutations are 
molecular markers of sensitivity to inhibitors of 
SRC family–TNK2 and JAK kinases and may 
provide a new avenue for therapy.
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